View Item 

Show simple item record

Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A

dc.contributor.authorKasuda, S.en_US
dc.contributor.authorKubo, A.en_US
dc.contributor.authorSakurai, Y.en_US
dc.contributor.authorIrion, S.en_US
dc.contributor.authorOhashi, K.en_US
dc.contributor.authorTatsumi, K.en_US
dc.contributor.authorNakajima, Y.en_US
dc.contributor.authorSaito, Y.en_US
dc.contributor.authorHatake, K.en_US
dc.contributor.authorPipe, Steven W.en_US
dc.contributor.authorShima, M.en_US
dc.contributor.authorYoshioka, A.en_US
dc.date.accessioned2010-06-01T18:49:02Z
dc.date.available2010-06-01T18:49:02Z
dc.date.issued2008-08en_US
dc.identifier.citationKASUDA, S.; KUBO, A.; SAKURAI, Y.; IRION, S.; OHASHI, K.; TATSUMI, K.; NAKAJIMA, Y.; SAITO, Y.; HATAKE, K.; PIPE, S. W.; SHIMA, M.; YOSHIOKA, A. (2008). "Establishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia A." Journal of Thrombosis and Haemostasis 6(8 ): 1352-1359. <http://hdl.handle.net/2027.42/72012>en_US
dc.identifier.issn1538-7933en_US
dc.identifier.issn1538-7836en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72012
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18485084&dopt=citationen_US
dc.format.extent283043 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2008 International Society on Thrombosis and Haemostasisen_US
dc.subject.otherCell-based Therapyen_US
dc.subject.otherEmbryonic Stem Cellsen_US
dc.subject.otherFactor VIIIen_US
dc.subject.otherHemophilia Aen_US
dc.titleEstablishment of embryonic stem cells secreting human factor VIII for cell-based treatment of hemophilia Aen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum†† Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationother* Department of Paediatrics, Nara Medical University, Kashihara, Naraen_US
dc.contributor.affiliationother† Department of Legal Medicine, Nara Medical University, Kashihara, Naraen_US
dc.contributor.affiliationother† Department of Legal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogoen_US
dc.contributor.affiliationother§ First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japanen_US
dc.contributor.affiliationother¶ Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY, USAen_US
dc.contributor.affiliationother** Department of Surgery, Nara Medical University, Kashihara, Nara, Japanen_US
dc.identifier.pmid18485084en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72012/1/j.1538-7836.2008.03022.x.pdf
dc.identifier.doi10.1111/j.1538-7836.2008.03022.xen_US
dc.identifier.sourceJournal of Thrombosis and Haemostasisen_US
dc.identifier.citedreferenceAntonarakis SE. Molecular genetics of coagulation factor VIII gene and haemophilia A. Haemophilia 1998; 4 ( Suppl. 2 ): 1 – 11.en_US
dc.identifier.citedreferenceManco-Johnson M. Hemophilia management: optimizing treatment based on patient needs. Curr Opin Pediatr 2005; 17: 3 – 6.en_US
dc.identifier.citedreferenceLillicrap D, Vandendriessche T, High K. Cellular and genetic therapies for haemophilia. Haemophilia 2006; 12 ( Suppl. 3 ): 36 – 41.en_US
dc.identifier.citedreferenceSarkar R, Tetreault R, Gao G, Wang L, Bell P, Chandler R, Wilson JM, Kazazian HH Jr. Total correction of hemophilia A mice with canine FVIII using an AAV  8 serotype. Blood 2004; 103: 1253 – 60.en_US
dc.identifier.citedreferenceKaiser J. Gene therapy. Side effects sideline hemophilia trial. Science 2004; 304: 1423 – 5.en_US
dc.identifier.citedreferenceSchuettrumpf J, Liu JH, Couto LB, Addya K, Leonard DG, Zhen Z, Sommer J, Arruda VR. Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. Mol Ther 2006; 13: 1064 – 73.en_US
dc.identifier.citedreferenceKo S, Tanaka I, Kanehiro H, Kanokogi H, Ori J, Shima M, Yoshioka A, Giles A, Nakajima Y. Preclinical experiment of auxiliary partial orthotopic liver transplantation as a curative treatment for hemophilia. Liver Transpl 2005; 11: 579 – 84.en_US
dc.identifier.citedreferenceOhashi K, Waugh JM, Dake MD, Yokoyama T, Kuge H, Nakajima Y, Yamanouchi M, Naka H, Yoshioka A, Kay MA. Liver tissue engineering at extrahepatic sites in mice as a potential new therapy for genetic liver diseases. Hepatology 2005; 41: 132 – 40.en_US
dc.identifier.citedreferenceKumaran V, Benten D, Follenzi A, Joseph B, Sarkar R, Gupta S. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost 2005; 3: 2022 – 31.en_US
dc.identifier.citedreferenceKyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002; 109: 29 – 37.en_US
dc.identifier.citedreferenceKubo A, Chen V, Kennedy M, Zahradka E, Daley GQ, Keller G. The homeobox gene HEX regulates proliferation and differentiation of hemangioblasts and endothelial cells during ES cell differentiation. Blood 2005; 105: 4590 – 7.en_US
dc.identifier.citedreferenceShibata M, Shima M, Morichika S, McVey J, Tuddenham EG, Tanaka I, Suzuki H, Nogami K, Minamoto Y, Hato T, Saenko EL, Scandella D, Yoshioka A. An alloantibody recognizing the FVIII A1 domain in a patient with CRM reduced haemophilia A due to deletion of a large portion of the A1 domain DNA sequence. Thromb Haemost 2000; 84: 442 – 8.en_US
dc.identifier.citedreferenceMiao HZ, Sirachainan N, Palmer L, Kucab P, Cunningham MA, Kaufman RJ, Pipe SW. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412 – 19.en_US
dc.identifier.citedreferenceFehling HJ, Lacaud G, Kubo A, Kennedy M, Robertson S, Keller G, Kouskoff V. Tracking mesoderm induction and its specification to the hemangioblast during embryonic stem cell differentiation. Development 2003; 130: 4217 – 27.en_US
dc.identifier.citedreferenceKubo A, Shinozaki K, Shannon JM, Kouskoff V, Kennedy M, Woo S, Fehling HJ, Keller G. Development of definitive endoderm from embryonic stem cells in culture. Development 2004; 131: 1651 – 62.en_US
dc.identifier.citedreferenceKaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352 – 62.en_US
dc.identifier.citedreferenceTada S, Era T, Furusawa C, Sakurai H, Nishikawa S, Kinoshita M, Nakao K, Chiba T, Nishikawa S. Characterization of mesendoderm: a diverging point of the definitive endoderm and mesoderm in embryonic stem cell differentiation culture. Development 2005; 132: 4363 – 74.en_US
dc.identifier.citedreferencePittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 2925 – 35.en_US
dc.identifier.citedreferenceToole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 1986; 83: 5939 – 42.en_US
dc.identifier.citedreferenceGouon-Evans V, Boussemart L, Gadue P, Nierhoff D, Koehler CI, Kubo A, Shafritz DA, Keller G. BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm. Nat Biotechnol 2006; 24: 1402 – 11.en_US
dc.identifier.citedreferenceBarbera JPM, Clements M, Thomas P, Rodriguez T, Meloy D, Kioussis D, Beddington RSP. The homeobox gene Hex is required in definitive endoderm tissues for normal forebrain, liver and thyroid formation. Development 2000; 127: 2433 – 45.en_US
dc.identifier.citedreferencePittman DD, Marquette KA, Kaufman RJ. Role of the B domain for factor VIII and factor V expression and function. Blood 1994; 84: 4214 – 25.en_US
dc.identifier.citedreferencePipe SW, Morris JA, Shah J, Kaufman RJ. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem 1998; 273: 8537 – 44.en_US
dc.identifier.citedreferenceShi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, Du LM, Desai D, Montgomery RR. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007; 5: 352 – 61.en_US
dc.identifier.citedreferencePipe SW, Saint-Remy JM, Walsh CE. New high-technology products for the treatment of haemophilia. Haemophilia 2004; 10 ( Suppl. 4 ): 55 – 63.en_US
dc.identifier.citedreferenceHubbard AR, Bevan SA, Weller LJ. Potency estimation of recombinant factor VIII: effect of assay method and standard. Br J Haematol 2001; 113: 533 – 6.en_US
dc.identifier.citedreferenceFujikawa T, Oh SH, Pi L, Hatch HM, Shupe T, Petersen BE. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol 2005; 166: 1781 – 91.en_US
dc.identifier.citedreferenceKolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, Sasse P, Rubenchik O, Fries JW, Wenzel D, Geisen C, Xia Y, Lu Z, Duan Y, Kettenhofen R, Jovinge S, Bloch W, Bohlen H, Welz A, Hescheler J, et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med 2006; 203: 2315 – 27.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1538-7836.2008.03022.x.pdf
Size:
276.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.